Patents Assigned to TissueGene, Inc.
  • Patent number: 7431922
    Abstract: The subject invention is related to a cell-mediated gene therapy treatment using a cell composition that includes bioadhesive material. The bioadhesive material allows targeted and localized delivery of therapeutic somatic cells to the site of interest.
    Type: Grant
    Filed: March 5, 2003
    Date of Patent: October 7, 2008
    Assignee: TissueGene, Inc.
    Inventors: Sun Uk Song, Youngsuk Yi, Kwan Hee Lee
  • Patent number: 7338655
    Abstract: The subject invention is related to a cell-mediated gene therapy treatment for orthopedic disease using a member belonging to the transforming growth factor-? (TGF-?) superfamily. TGF-? gene therapy as a new treatment method for degenerative arthritis is demonstrated. After transfection of TGF-? cDNA expression vectors into fibroblasts (NIH 3T3-TGF-?1), the cells were injected into rabbit achilles tendon and knee joints with artificially-made cartilage defects. Intratendinous injections were performed to determine the optimal concentration for in vivo expression. Partially defected cartilage model was made to simulate degenerative arthritis of the knee joint. The partial cartilage defect treated with the cell-mediated gene therapy procedure was covered by newly formed hyaline cartilage which indicates that the cells survived and stimulated matrix formation in this area. Completely denuded cartilage areas were covered by fibrous collagen.
    Type: Grant
    Filed: November 8, 2000
    Date of Patent: March 4, 2008
    Assignee: Tissuegene, Inc.
    Inventors: Moon Jong Noh, Kyoung Ae Kang, Kwan Hee Lee
  • Patent number: 7282200
    Abstract: The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been transfected or transduced with the gene, wherein endogenously existing forms of the second population of mammalian cells are decreased at the target site, and wherein generation of the therapeutic protein by the first population of mammalian cells at the target site stimulates the second population cells to induce a therapeutic effect.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: October 16, 2007
    Assignee: Tissuegene, Inc.
    Inventors: Sun Uk Song, Youngsuk Yi, Kwan Hee Lee, Moon Jong Noh
  • Patent number: 7005127
    Abstract: The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been transfected or transduced with the gene, wherein endogenously existing forms of the second population of mammalian cells are decreased at the target site, and wherein generation of the therapeutic protein by the first population of mammalian cells at the target site stimulates the second population cells to induce a therapeutic effect.
    Type: Grant
    Filed: March 5, 2003
    Date of Patent: February 28, 2006
    Assignee: TissueGene, Inc.
    Inventors: Sun Uk Song, Youngsuk Yi, Kwan Hee Lee, Moon Jong Noh
  • Publication number: 20060019396
    Abstract: The present application discloses a MoMSV/MoMLV hybrid-based retroviral vector, wherein gag and pol genes are completely removed.
    Type: Application
    Filed: June 7, 2005
    Publication date: January 26, 2006
    Applicant: TISSUEGENE, INC.
    Inventors: Sung Ho HAHM, Dug Keun LEE, Kwan Hee LEE, Youngsuk YI
  • Publication number: 20060014288
    Abstract: The present application describes a method of regenerating nerve, which steps include generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter; transfecting in vitro a population of cultured cells with the recombinant vector, resulting in a population of the cultured cells; and transplanting the transfected cells to an area near an injured nerve, such that expression of the DNA sequence within the area near the injured nerve causes regeneration of the nerve.
    Type: Application
    Filed: June 23, 2005
    Publication date: January 19, 2006
    Applicant: TISSUEGENE, INC.
    Inventors: Chang Hwan Kim, Kwan Hee Lee
  • Patent number: 6797703
    Abstract: The subject invention is related to a cell-mediated gene therapy treatment for orthopedic disease using a member belonging to the transforming growth factory-&bgr; (TGF-&bgr;) superfamily. TGF-&bgr; gene therapy as a new treatment method for degenerative arthritis is demonstrated. After transfection of TGF-&bgr; cDNA expression vectors into fibroblasts (NIH 3T3-TGF-&bgr;1), the cells were injected into rabbit achilles tendon and knee joints with artificially-made cartilage defects. Intratendinous injections were performed to determine the optimal concentration for in vivo expression. Partially defected cartilage model was made to simulate degenerative arthritis of the knee joint. The partial cartilage defect treated with the cell-mediated gene therapy procedure was covered by newly formed hyaline cartilage which indicates that the cells survived and stimulated matrix formation in this area. Completely denuded cartilage areas were covered by fibrous collagen.
    Type: Grant
    Filed: November 1, 2000
    Date of Patent: September 28, 2004
    Assignee: Tissuegene, Inc.
    Inventors: Moon Jong Noh, Kyoung Ae Kang, Kwan Hee Lee